Status:
TERMINATED
JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events
Lead Sponsor:
AstraZeneca
Conditions:
Elevated High-sensitivity C-Reactive Protein (hsCRP)
Eligibility:
All Genders
50+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine the safety and effectiveness of long-term therapy with rosuvastatin compared with a placebo, and to evaluate whether treatment with rosuvastatin might be effe...
Detailed Description
AstraZeneca announced it has decided to stop the CRESTOR JUPITER clinical study early based on a recommendation from an Independent Data Monitoring Board and the JUPITER Steering Committee, which met ...
Eligibility Criteria
Inclusion
- Men 50 years or older, women 60 years or older
- Low to normal levels of low density lipoprotein (LDL) cholesterol (\< 130mg/dL)
- Elevated levels of C-Reactive Protein (CRP) \> 2.0 mg/L
Exclusion
- History of cardiovascular or cerebrovascular events
- Active liver disease
- Diabetes mellitus
- Uncontrolled hypertension or hypothyroidism
- History of certain malignancies
- Chronic inflammatory conditions
- History of alcohol or drug abuse
Key Trial Info
Start Date :
February 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2008
Estimated Enrollment :
17802 Patients enrolled
Trial Details
Trial ID
NCT00239681
Start Date
February 1 2003
End Date
September 1 2008
Last Update
March 24 2014
Active Locations (856)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Birmingham, Alabama, United States
2
Research Site
Calera, Alabama, United States
3
Research Site
Columbiana, Alabama, United States
4
Research Site
Decatur, Alabama, United States